But supply problems are getting worse.
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
In the second quarter it paid to be a leading obesity company. As for Covid, not so much.
But large gains for some big pharma players flatter the overall figures.
Developers brush off antitrust scrutiny and drug price curbs and succumb to the urge to merge.